A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs

Huang, Wen Chang; Hu, Shang Hsiu; Liu, Kun Ho; Chen, San Yuan; Liu, Dean Mo

doi:10.1016/j.jconrel.2009.07.002

Cited by 58 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, pulsatile drug delivery systems (PDDS) have drawn attention as they allow repeatable and reliable drug release flux for clinical needs. Further, external stimulation signals such as temperature variation, 9,10 magnetic fields, [11][12][13][14] and electric fields, [15][16][17][18][19][20][21] can be used in PDDS to trigger or control drug release rates, thereby allowing remote control of local drug administration. Most of the PDDS devices are composed of a drug-loading container covered with a functional membrane, with drug release rates through the functional membrane controlled by modulating the external stimulations.…”

Section: Introductionmentioning

confidence: 99%

Programmable and on-demand drug release using electrical stimulation

Sun

et al. 2015

Biomicrofluidics

View full text Add to dashboard Cite

Recent advancement in microfabrication has enabled the implementation of implantable drug delivery devices with precise drug administration and fast release rates at specific locations. This article presents a membrane-based drug delivery device, which can be electrically stimulated to release drugs on demand with a fast release rate. Hydrogels with ionic model drugs are sealed in a cylindrical reservoir with a separation membrane. Electrokinetic forces are then utilized to drive ionic drug molecules from the hydrogels into surrounding bulk solutions. The drug release profiles of a model drug show that release rates from the device can be electrically controlled by adjusting the stimulated voltage. When a square voltage wave is applied, the device can be quickly switched between on and off to achieve pulsatile release. The drug dose released is then determined by the duration and amplitude of the applied voltages. In addition, successive on/off cycles can be programmed in the voltage waveforms to generate consistent and repeatable drug release pulses for on-demand drug delivery. V C 2015 AIP Publishing LLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Programmable and on-demand drug release using electrical stimulation

Sun

et al. 2015

Biomicrofluidics

View full text Add to dashboard Cite

show abstract

“…19 Some preliminary studies using nanoparticles like liposomes and polymers to encapsulate antiepileptic agents have shown anticonvulsive effects in epilepsy models. [20][21][22] However, these studies still use inert nanocarriers without biological activity, which may affect their efficacy in P-gp mediated drug-resistant epilepsy. In addition, some of these studies still used delivery of drugloaded nanoparticles via invasive routes, eg, local intracerebral implantation.…”

Section: Introductionmentioning

confidence: 99%

Enhanced brain delivery of lamotrigine with Pluronic® P123-based nanocarrier

Liu¹,

Wang²,

Zhou³

et al. 2014

IJN

View full text Add to dashboard Cite

Background P-glycoprotein (P-gp) mediated drug efflux across the blood–brain barrier (BBB) is an important mechanism underlying poor brain penetration of certain antiepileptic drugs (AEDs). Nanomaterials, as drug carriers, can overcome P-gp activity and improve the targeted delivery of AEDs. However, their applications in the delivery of AEDs have not been adequately investigated. The objective of this study was to develop a nano-scale delivery system to improve the solubility and brain penetration of the antiepileptic drug lamotrigine (LTG). Methods LTG-loaded Pluronic ® P123 (P123) polymeric micelles (P123/LTG) were prepared by thin-film hydration, and brain penetration capability of the nanocarrier was evaluated. Results The mean encapsulating efficiency for the optimized formulation was 98.07%; drug-loading was 5.63%, and particle size was 18.73 nm. The solubility of LTG in P123/LTG can increase to 2.17 mg/mL, making it available as a solution. The in vitro release of LTG from P123LTG presented a sustained-release property. Compared with free LTG, the LTG-incorporated micelles accumulated more in the brain at 0.5, 1, and 4 hours after intravenous administration in rats. Pretreatment with systemic verapamil increased the rapid brain penetration of free LTG but not P123/LTG. Incorporating another P-gp substrate (Rhodamine 123) into P123 micelles also showed higher efficiency in penetrating the BBB in vitro and in vivo. Conclusion These results indicated that P123 micelles have the potential to overcome the activity of P-gp expressed on the BBB and therefore show potential for the targeted delivery of AEDs. Future studies are necessary to further evaluate the appropriateness of the nanocarrier to enhance the efficacy of AEDs.

show abstract

“…Cells were incubated for 2 days at 37°C with 200µl of either freshly prepared solutions of DTX at various concentrations or with the drug solution released from the device under various number of device actuations. Cell viability was 5 …”

Section: Controlled Release and Cell Viability Studiesmentioning

confidence: 99%

“…Alternatively, external magnetic actuation using magnetic micropumps with microchannels and microvalves have been proposed for drug delivery [4]; however, most of these devices require relatively high pressure for operation (over 3 kPa) due to friction loss in the microchannels. A magnetic stimulus has been used as a trigger for antiepileptic drug release, both in vitro and in vivo, from a flexible membrane, made by electrodeposition of drug-carrying core-shell magnetic nanoparticles [5]. Although switchable release behavior was demonstrated, it may not be a suitable device for treatment of chronic diseases, where long-term drug release with highly controlled rates is desired.…”

Section: Introductionmentioning

confidence: 99%

Delivery of an anti-cancer drug from a magnetically controlled MEMS device show cytotoxicity in PC3 and HUVEC cells

Pirmoradi

Jackson

Burt

et al. 2011

2011 16th International Solid-State Sensors, Actuators and Microsystems Conference

View full text Add to dashboard Cite

We have developed a magnetically controlled MEMS drug delivery device for on-demand release of defined quantities of an anti-cancer drug, docetaxel (DTX). A drug-loaded micro reservoir (∅6mm×550µm) is sealed by a 40µm-thick elastic magnetic PDMS (polydimethylsiloxane) membrane with a laser-drilled aperture (~100×100µm 2 ). Discharge of the drug solution and the release rates are controlled by an external magnetic field. Controlled and reproducible release rates of DTX have been achieved for 35 days. We report on the cytotoxicity of the released drug from the device (monitored as cell viability) and show that DTX maintains cytotoxic effects for two months.

show abstract

A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs

Cited by 58 publications

References 20 publications

Programmable and on-demand drug release using electrical stimulation

Programmable and on-demand drug release using electrical stimulation

Enhanced brain delivery of lamotrigine with Pluronic® P123-based nanocarrier

Delivery of an anti-cancer drug from a magnetically controlled MEMS device show cytotoxicity in PC3 and HUVEC cells

Contact Info

Product

Resources

About

A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs

Cited by 58 publications

References 20 publications

Programmable and on-demand drug release using electrical stimulation

Programmable and on-demand drug release using electrical stimulation

Enhanced brain delivery of lamotrigine with Pluronic&reg; P123-based nanocarrier

Delivery of an anti-cancer drug from a magnetically controlled MEMS device show cytotoxicity in PC3 and HUVEC cells

Contact Info

Product

Resources

About

Enhanced brain delivery of lamotrigine with Pluronic® P123-based nanocarrier